- Home
- ASRT vs IMUX Comparison
ASRT vs IMUX Comparison
Compare ASRT & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASRT
- IMUX
- Stock Information
- Founded
- ASRT 1995
- IMUX 2016
- Country
- ASRT United States
- IMUX United States
- Employees
- ASRT N/A
- IMUX N/A
- Industry
- ASRT Biotechnology: Pharmaceutical Preparations
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- ASRT Health Care
- IMUX Health Care
- Exchange
- ASRT Nasdaq
- IMUX Nasdaq
- Market Cap
- ASRT 78.3M
- IMUX 102.2M
- IPO Year
- ASRT 1997
- IMUX N/A
- Fundamental
- Price
- ASRT $0.72
- IMUX $1.12
- Analyst Decision
- ASRT Strong Buy
- IMUX Strong Buy
- Analyst Count
- ASRT 3
- IMUX 6
- Target Price
- ASRT $3.25
- IMUX $12.67
- AVG Volume (30 Days)
- ASRT 329.2K
- IMUX 904.4K
- Earning Date
- ASRT 03-12-2025
- IMUX 05-07-2025
- Dividend Yield
- ASRT N/A
- IMUX N/A
- EPS Growth
- ASRT N/A
- IMUX N/A
- EPS
- ASRT N/A
- IMUX N/A
- Revenue
- ASRT $124,961,000.00
- IMUX N/A
- Revenue This Year
- ASRT N/A
- IMUX N/A
- Revenue Next Year
- ASRT $1.84
- IMUX N/A
- P/E Ratio
- ASRT N/A
- IMUX N/A
- Revenue Growth
- ASRT N/A
- IMUX N/A
- 52 Week Low
- ASRT $0.68
- IMUX $0.92
- 52 Week High
- ASRT $1.80
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- ASRT 34.96
- IMUX 51.41
- Support Level
- ASRT $0.74
- IMUX $1.06
- Resistance Level
- ASRT $0.83
- IMUX $1.22
- Average True Range (ATR)
- ASRT 0.04
- IMUX 0.09
- MACD
- ASRT -0.00
- IMUX -0.01
- Stochastic Oscillator
- ASRT 26.90
- IMUX 37.50
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.